Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARD3 long-term extension study of ESK-001 in moderate to severe plaque psoriasis
2024-511166-36-00Phase 3Authorised
- Sponsor
- Alumis Inc.
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, open-label trial of envudeucitinib in plaque psoriasis (2 arms), sponsored by Alumis Inc. Primary endpoint: Treatment-emergent adverse events and serious adverse events. Planned start Jun 2025; status: authorised.
02
Drugs
envudeucitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2024-511166-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511166-36-00.